Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)

Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen-4 (CTLA-4). Combinations o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Agarwala, Sanjiv S., Warner, Allison Betof, Ernstoff, Marc S., Fox, Bernard A., Gajewski, Thomas F., Galon, Jérôme, Garbe, Claus, Gastman, Brian R., Gershenwald, Jeffrey E., Kalinski, Pawel, Krogsgaard, Michelle, Leidner, Rom S., Lo, Roger S., Menzies, Alexander M., Michielin, Olivier, Poulikakos, Poulikos I., Weber, Jeffrey S., Caracò, Corrado, Osman, Iman, Puzanov, Igor, Thurin, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375730/
https://www.ncbi.nlm.nih.gov/pubmed/37507765
http://dx.doi.org/10.1186/s12967-023-04325-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375730/
https://www.ncbi.nlm.nih.gov/pubmed/37507765
http://dx.doi.org/10.1186/s12967-023-04325-x

Ejemplares similares